DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Dare Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.71−0.02 (-2.57%)
Close on Oct 19, 2026
- Market cap
- $10.51M
- P/E (TTM)
- –
- Dividend yield
- –
Dare Bioscience, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2016 | FY2015 | FY2014 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| License And Collaboration Revenues | $12.00M | $11.00M | $11.00M | $10.00M | – | – | – | – | 1164.8% | +9.1% |
| License | $1.03M | $9.78K | $1.00M | $10.00M | – | – | – | – | 100.0% | +10429.4% |
| Royalty Revenue | – | $18.00K | $7.90K | – | $26.00K | – | – | – | – | – |
| Research and development services and royalty revenue | – | $9.78K | $7.89K | $0 | – | – | – | – | – | – |
| Milestone revenue | – | $0 | $1.80M | $0 | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Dare Bioscience's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.